OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) approved 'daznelimgene lisbac' for the non-proprietary name for the Company's HER2 targeted Listeria monocytogenes-based cancer immunotherapy product candidate OST-HER2. OST-HER2 is currently being developed for the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma.

Each INN name is unique and is used to identify active pharmaceutical ingredients. Each active substance that is to be marketed as a pharmaceutical must be granted a unique name of worldwide acceptability to ensure clear identification, safe prescription and dispensing of medicines. OS Therapies will begin to transition towards the use of diznalimgene lisbac alongside the OST-HER2 in future communications.